Here's Why You Should Retain Olin Stock in Your Portfolio

Olin (OLN) is targeting $100M–$120M of cost savings in 2026 under its Beyond250 program and at least $250M of run-rate savings by 2028, with the planned all-stock merger with Huntsman expected to add $400M+ in synergies (close expected H1 2027). Offsetting this, weak global chemical demand, Asian import competition, the Freeport VCM outage (cutting Q2 adjusted EBITDA by ~$40M and expected to reduce Q3 by another ~$20M), lower EDC/export caustic soda pricing, elevated leverage (net debt $2.85B; net debt/adj. EBITDA 5.0x vs 4.1x at YE2025), and negative H1 operating cash flow (-$40.7M vs +$126.3M) may pressure near-term margins, free cash flow and deleveraging. The stock is down 26% over the past year versus the industry’s +2.2%.

Analysis

The equity is still being priced like a cyclical recovery story, but the balance sheet says it behaves more like a levered option on a late-cycle margin rebound. In that setup, incremental cost savings are valuable mostly to equity only after the business proves it can turn gross profit into free cash flow; until then, they mainly slow credit pressure rather than create immediate rerating. That makes OLN vulnerable to “good news, bad stock” behavior if operating improvements arrive alongside weak cash conversion.

The bigger second-order issue is competitive discipline: persistent import pressure in epoxy and weak chlor-alkali pricing cap the ability to keep passing through costs, so any benefit from lower feedstock or restructuring can be competed away faster than consensus expects. The outage-related earnings drag is temporary, but it highlights how thin the margin buffer is; if pricing does not recover into the next two quarters, the market will likely treat 5x leverage as the binding constraint and discount the merger synergies heavily. HUN is the cleaner way to express any deal spread, but the real winner may be higher-quality materials names with better earnings visibility and less refinancing risk, such as MTRN.

Contrarian view: the market may be underestimating how much of the synergy story is already offset by integration costs, legacy liabilities, and working-capital noise. If 2H cash generation fails to normalize, the “deleveraging” narrative turns into an equity dilution or asset-sale question well before 2027. The key falsifier is a sustained improvement in operating cash flow and net leverage moving decisively below management’s target ahead of schedule; absent that, rallies should be sold rather than chased.

Key Decisions for Investors

• Short OLN on strength into the next catalyst window (3Q26 print / guidance update); thesis breaks if adjusted EBITDA and operating cash flow both improve enough to show clear deleveraging trajectory.
• Pair trade: long MTRN / short OLN for 3-6 months to express quality-over-cyclical-leverage in basic materials; use this if you want materials exposure without balance-sheet risk.
• For event-driven accounts, monitor HUN merger spread rather than own OLN outright; only add on widening if deal-break risk rises, otherwise the spread is likely the cleaner expression of the transaction.
• Set an alert on OLN credit and cash flow metrics: if net debt remains near 5x and free cash flow stays negative after 2H working-capital unwind, increase short exposure or buy downside protection.